𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Revisiting safety of minocycline as neuroprotection in Huntington's disease

✍ Scribed by Norman Reynolds


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
36 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


A futility study of minocycline in Hunti
✍ Dr. Merit Cudkowicz; The Huntington Study Group DOMINO Investigators πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 1 views

## Abstract This study assessed the futility of proceeding with a Phase 3 clinical trial of minocycline as a disease‐modifying treatment for Huntington's disease (HD). One hundred fourteen research participants with HD were randomized, 87 to minocycline (200 mg/d) and 27 to placebo. The change in T

Neuroprotective effects of phytocannabin
✍ Onintza Sagredo; M. Ruth Pazos; Valentina Satta; JosΓ© A. Ramos; Roger G. Pertwee πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 457 KB

We studied whether combinations of botanical extracts enriched in either D 9 -tetrahydrocannabinol (D 9 -THC) or cannabidiol (CBD), which are the main constituents of the cannabis-based medicine Sativex, provide neuroprotection in rat models of Huntington's disease (HD). We used rats intoxicated wit

Myopathy as a first symptom of Huntingto
✍ Christoph M. Kosinski; Christiane Schlangen; Frank N. Gellerich; Zemfira Gizatul πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 172 KB πŸ‘ 1 views

## Abstract A semi professional marathon runner at risk for Huntington's disease (HD) (43 CAG repeats) developed signs of a slowly progressive myopathy with exercise‐induced muscle fatigue, pain, elevated creatine kinase level, and worsening of his running performance many years before first signs